13-05-2025
Sabra Health Care price target raised to $19 from $18 at Scotiabank
Scotiabank analyst Nicholas Yulico raised the firm's price target on Sabra Health Care (SBRA) to $19 from $18 and keeps a Sector Perform rating on the shares. The firm is adjusting its estimates on U.S. Real Estate & REITs in its coverage following Q1 results, the analyst tells investors. Quarterly results contained some negative surprises, but generally played out as expected, with most companies maintaining FY25 guidance, the firm notes. Real estate fundamentals tend to lag, so many are looking to see the potential impact of the slowing economy on H2 2025 results, the firm adds.
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SBRA:
Disclaimer & DisclosureReport an Issue
Sabra Health Care REIT Reports Strong Q1 2025 Results
Sabra Healthcare REIT Reports Record Highs and Strong Pipeline
Hold Rating on Sabra Healthcare REIT Amid Strong Financials and Strategic Uncertainties
Sabra Healthcare REIT Expands Senior Housing Portfolio
Sabra Health Care reports Q1 FFO 37c, consensus 36c
